Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial

Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial

Abstract Currently, there are no clinically actionable biomarkers to predict patient to cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) plus endocrine therapy for hormone receptor (HR)[+]/ human epidermal growth factor receptor 2 (HER2)[-] advanced breast cancer (ABC). Herein, we report an exp...

Full description

Saved in:
Bibliographic Details
Main Authors: Joan Albanell, Angelo Gámez Pozo, Carlos L. Arteaga, Meritxell Bellet, Federico Rojo, Abel González, Beatriz Bellosillo, Violeta Serra, Petra Gener, José Antonio Guerrero, Eileen Shimizu, Mario Mancino, Jose Rodríguez-Morató, Leonardo Mina, José Manuel Pérez-García, Javier Cortés, Antonio Llombart-Cussac
Format: Article
Language:English
Published: Nature Portfolio 2025-06-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-025-00777-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41523-025-00777-0

Similar Items